Efter peroral eller intravenøs administration af 14C irbesartan, kan 80- 85% af den cirkulerende radioaktivitet i plasma tilskrives uomdannet irbesartan.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.